Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults With Atopic Dermatitis

NCT07150845 is registered in ClinicalTrials.gov with Evommune, Inc. as lead sponsor.

NCT NCT07150845
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07150845 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults With Atopic Dermatitis
Lead sponsor
Evommune, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 26, 2025
Completion date
August 3, 2026
Enrollment
121 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis